Vivimed Labs stock rises 2.44% as it receives approval for six products
It received approvals for 3 ophthalmic products from its state of the art sterile Ophthalmic facility and 3 oral liquid suspension products.
Nov 23, 2020 06:11 IST India Infoline News Service

1. Ambroxol Hydrochloride Syrup 15mg/5ml100ml under brand name AMBRO Kid
• Tracheobronchitis
• Acute exacerbations of bronchitis
Bromhexine hydrochloride is used to treat breathing difficulties caused by excessive mucus secretions in the air passages associated with respiratory tract infections.
Guaifenesin (Guaiphenesin or Glyceryl Guaiacolate) is an expectorant. It usually solves over the counter and helps treat congestion in your chest and throat by the common cold, infections, or allergies. The medicine is for a cough and cold to make it easier to cough out through your mouth.
Menthol is a topical analgesic. It works by temporarily relieving minor pain.
3. Terbutaline sulphate, Bromhexine HCI, Guaifenesin, Menthol Expectorant under brand name BROXIMED EXPECTORANT 100ML
Bromhexine hydrochloride is used to treat breathing difficulties caused by excessive mucus secretions in the air passages associated with respiratory tract infections.
Guaifenesin (Guaiphenesin or Glyceryl Guaiacolate) is an expectorant. It usually solves over the counter and helps treat congestion in your chest and throat by the common cold, infections, or allergies. The medicine is for a cough and cold to make it easier to cough out through your mouth.
Menthol is a topical analgesic. It works by temporarily relieving minor pain.
4. Dorzolamide Eye drops 5ml under brand name DORZOVIV
5. Moxifloxacin eye drops Sml under brand name MOXSIVIV
6. Ofloxacin Eye Drops Sml under brand name ZENOFLOKS
Commenting on the Approvals, Ramesh Krishnamurthy, CEO of Vivimed Labs Ltd said, "These 6 approvals mark yet another significant milestone for increasing the exports of Vivimed own brands to multiple countries. Vivimed shall be launching 10+ new products in 03/04 FY 2021. Our purpose is to market innovative & top quality formulations at affordable prices. The approvals are testimony to Vivimed's growth strategy" .
Vivimed was trading at Rs16.80 per piece up by Rs0.4 or 2.44% from its previous closing of Rs16.40 on the BSE, at around 11.40am.